Alykhan Nagji, MD, provides a brief overview of the landscape surrounding the treatment of patients with stage-III resectable NSCLC.
Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.